S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
Log in
NYSE:EW

Edwards Lifesciences Stock Forecast, Price & News

$83.97
-0.48 (-0.57 %)
(As of 02/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$82.92
Now: $83.97
$85.09
50-Day Range
$81.92
MA: $86.30
$90.67
52-Week Range
$51.51
Now: $83.97
$92.08
Volume2.10 million shs
Average Volume2.68 million shs
Market Capitalization$52.44 billion
P/E Ratio67.18
Dividend YieldN/A
Beta0.97
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral valve diseases, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Edwards Lifesciences logo

Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP28176E10
Phone949-250-2500
Employees13,900
Year Founded1958

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.35 billion
Cash Flow$1.91 per share
Book Value$6.63 per share

Profitability

Net Income$1.05 billion

Miscellaneous

Market Cap$52.44 billion
Next Earnings Date4/22/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.64 out of 5 stars

Medical Sector

277th out of 1,957 stocks

Surgical Appliances & Supplies Industry

9th out of 40 stocks

Analyst Opinion: 2.3Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
$83.97
-0.48 (-0.57 %)
(As of 02/25/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EW News and Ratings via Email

Sign-up to receive the latest news and ratings for EW and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Edwards Lifesciences (NYSE:EW) Frequently Asked Questions

Is Edwards Lifesciences a buy right now?

19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 2 sell ratings, 5 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Edwards Lifesciences stock.
View analyst ratings for Edwards Lifesciences
or view top-rated stocks.

What stocks does MarketBeat like better than Edwards Lifesciences?

Wall Street analysts have given Edwards Lifesciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Edwards Lifesciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Edwards Lifesciences' next earnings date?

Edwards Lifesciences is scheduled to release its next quarterly earnings announcement on Thursday, April 22nd 2021.
View our earnings forecast for Edwards Lifesciences
.

How were Edwards Lifesciences' earnings last quarter?

Edwards Lifesciences Co. (NYSE:EW) released its earnings results on Tuesday, January, 26th. The medical research company reported $0.50 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.53 by $0.03. The medical research company had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.18 billion. Edwards Lifesciences had a net margin of 18.18% and a trailing twelve-month return on equity of 29.00%. The company's revenue was up 1.5% compared to the same quarter last year. During the same period last year, the business earned $1.46 EPS.
View Edwards Lifesciences' earnings history
.

How has Edwards Lifesciences' stock been impacted by COVID-19?

Edwards Lifesciences' stock was trading at $65.79 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EW stock has increased by 27.6% and is now trading at $83.97.
View which stocks have been most impacted by COVID-19
.

When did Edwards Lifesciences' stock split? How did Edwards Lifesciences' stock split work?

Shares of Edwards Lifesciences split on the morning of Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly minted shares were issued to shareholders after the market closes on Monday, May 18th 2020. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 300 shares after the split.

What guidance has Edwards Lifesciences issued on next quarter's earnings?

Edwards Lifesciences issued an update on its FY21 earnings guidance on Wednesday, January, 27th. The company provided EPS guidance of $2.00-2.20 for the period, compared to the Thomson Reuters consensus estimate of $2.13. The company issued revenue guidance of $4.90-5.30 billion, compared to the consensus revenue estimate of $5.10 billion.

What price target have analysts set for EW?

19 analysts have issued 1-year target prices for Edwards Lifesciences' shares. Their forecasts range from $51.67 to $111.00. On average, they expect Edwards Lifesciences' stock price to reach $91.54 in the next twelve months. This suggests a possible upside of 9.0% from the stock's current price.
View analysts' price targets for Edwards Lifesciences
or view top-rated stocks among Wall Street analysts.

Who are Edwards Lifesciences' key executives?

Edwards Lifesciences' management team includes the following people:
  • Mr. Michael A. Mussallem, Chairman & CEO (Age 68, Pay $3.64M)
  • Mr. Scott B. Ullem, Corp. VP & CFO (Age 54, Pay $1.42M) (LinkedIn Profile)
  • Mr. Donald E. Bobo Jr., Corp. VP of Strategy & Corp. Devel. (Age 59, Pay $1.36M) (LinkedIn Profile)
  • Mr. Larry L. Wood, Corp. VP of Transcatheter Aortic Valve Replacement (Age 55, Pay $1.46M) (LinkedIn Profile)
  • Mr. Jean-Luc Lemercier, Corp. VP of Europe, Middle East, Africa, Canada & Latin America (Age 64, Pay $1.33M) (LinkedIn Profile)
  • Dr. Todd J. Brinton, Corp. VP of Advanced Technology & Chief Scientific Officer (LinkedIn Profile)
  • Mark Wilterding, VP of Investor Relations
  • Mr. Arnold A. Pinkston, Corp. VP & Gen. Counsel (Age 62) (LinkedIn Profile)
  • Mr. Dirksen J. Lehman, Corp. VP of Public Affairs (LinkedIn Profile)
  • Ms. Christine Z. McCauley, Corp. VP of HR (Age 56) (LinkedIn Profile)

What is Michael A. Mussallem's approval rating as Edwards Lifesciences' CEO?

389 employees have rated Edwards Lifesciences CEO Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among Edwards Lifesciences' employees.

Who are some of Edwards Lifesciences' key competitors?

What other stocks do shareholders of Edwards Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), The Home Depot (HD), salesforce.com (CRM), The Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS).

What is Edwards Lifesciences' stock symbol?

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Who are Edwards Lifesciences' major shareholders?

Edwards Lifesciences' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (9.40%), Bank of New York Mellon Corp (3.50%), Brown Advisory Inc. (2.18%), Alliancebernstein L.P. (2.06%), Sands Capital Management LLC (1.86%) and Janus Henderson Group PLC (1.56%). Company insiders that own Edwards Lifesciences stock include Catherine M Szyman, Donald E Bobo Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link.
View institutional ownership trends for Edwards Lifesciences
.

Which institutional investors are selling Edwards Lifesciences stock?

EW stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Alliancebernstein L.P., Jennison Associates LLC, Sands Capital Management LLC, BlackRock Inc., Northern Trust Corp, Charles Schwab Investment Management Inc., and Schroder Investment Management Group. Company insiders that have sold Edwards Lifesciences company stock in the last year include Catherine M Szyman, Donald E Bobo Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers, and Scott B Ullem.
View insider buying and selling activity for Edwards Lifesciences
or view top insider-selling stocks.

Which institutional investors are buying Edwards Lifesciences stock?

EW stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Bank of New York Mellon Corp, Brown Advisory Inc., Ownership Capital B.V., Jackson Square Partners LLC, Royal London Asset Management Ltd., Ardevora Asset Management LLP, and Fisher Asset Management LLC.
View insider buying and selling activity for Edwards Lifesciences
or or view top insider-buying stocks.

How do I buy shares of Edwards Lifesciences?

Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Edwards Lifesciences' stock price today?

One share of EW stock can currently be purchased for approximately $83.97.

How much money does Edwards Lifesciences make?

Edwards Lifesciences has a market capitalization of $52.44 billion and generates $4.35 billion in revenue each year. The medical research company earns $1.05 billion in net income (profit) each year or $1.86 on an earnings per share basis.

How many employees does Edwards Lifesciences have?

Edwards Lifesciences employs 13,900 workers across the globe.

Does Edwards Lifesciences have any subsidiaries?

The following companies are subsidiares of Edwards Lifesciences: BMEYE, CAS Medical Systems, CardiAQ Valve Technologies, Edwards Lifesciences (Japan) Limited, Edwards Lifesciences AG, Edwards Lifesciences Holding B.V., Edwards Lifesciences Innovation Holding LLC, Edwards Lifesciences LLC, Edwards Lifesciences Services GmbH, Embrella Cardiovascular, Harpoon Medical, Myocor, Percutaneous Valve Technologies, Valtech Cardio, and Whitland Research.

When was Edwards Lifesciences founded?

Edwards Lifesciences was founded in 1958.

What is Edwards Lifesciences' official website?

The official website for Edwards Lifesciences is www.edwards.com.

Where are Edwards Lifesciences' headquarters?

Edwards Lifesciences is headquartered at ONE EDWARDS WAY, IRVINE CA, 92614.

How can I contact Edwards Lifesciences?

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at 949-250-2500 or via email at [email protected]


This page was last updated on 2/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.